Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Indication: Sunvozertinib for Untreated Advanced NSCLC with EGFR Exon 20 Insertions
In this international phase 3 trial, first-line sunvozertinib significantly improved progression-free survival and objective response rate compared to carboplatin-pemetrexed chemot
New Reference: Lorlatinib for ALK+ NSCLC
This 7-year update of the CROWN trial demonstrated that lorlatinib maintained unprecedented long-term progression-free survival benefit compared to crizotinib in advanced ALK-posit
New Reference: Encorafenib-Cetuximab with FOLFIRI in bRAF V600E Metastatic Colorectal Cancer
In this phase III randomized study, encorafenib plus cetuximab combined with FOLFIRI significantly improved objective response rate, progression-free survival, and overall survival
New Protocol: Camrelizumab with Apatinib for Chordoma
This phase II trial demonstrated that the combination of camrelizumab and apatinib in refractory chordoma achieved an objective response rate of 24.2% by RECIST and 48.5% by Choi c
New Reference: Cabozantinib with Nivolumab and Ipilimumab for Interm/High Risk RCC
The phase III COSMIC-313 study demonstrated that adding cabozantinib to nivolumab and ipilimumab significantly improved progression-free survival and objective response rate in pat
New Protocol: Oral Decitabine/Cedazuridine with Venetoclax for AML
This single-centre phase 2 study demonstrates that oral ASTX727 plus venetoclax is effective and tolerable in older or unfit patients with acute myeloid leukemia, inducing rapid re
New Indication: Zongertinib for HER2-Mutated Advanced NSCLC
In this phase 1b multicohort study, first-line zongertinib demonstrated a 76% objective response rate with durable responses and a median progression-free survival of 14.4 months i
New Protocol: Periop Toripalimab with Chemotherapy for Esophageal Cancer
In this phase II randomized trial with 3-year follow-up, perioperative toripalimab plus chemotherapy significantly improved event-free survival and overall survival compared to che
New Reference: Retifanlimab with Carboplatin – Paclitaxel for Advanced Anal Cancer
In this phase 3 randomized trial of patients with advanced squamous cell carcinoma of the anal canal, retifanlimab combined with carboplatin-paclitaxel significantly improved progr
